The top analyst upgrades, downgrades and other research calls from Tuesday include Agilent, Apple, Citigroup, Exxon, M&T Bank, Snap, Toyota and Twitter.
This partnership should be fairly transformative for BeiGene, seeing as it can start making some actual money.
Chris Lange The top analyst upgrades, downgrades and other research calls from Friday include Bluebird, Celgene, Coach, 58.com, Gold Fields, Nike, Rite Aid, Vipshop and Waste Management.
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia.
Chris Lange Friday’s top analyst upgrades, downgrades and initiations include Celgene, Kroger, Nike, Skyworks Solutions and Western Digital.
The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has screened the Credit Suisse Focus List to look for the stock for which Credit Suisse sees the most in implied total returns.
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The top analyst upgrades, downgrades and other research calls on Friday include Celgene, Continental Resources, Hess, Renewable Energy, U.S. Bancorp and Zynga.
24/7 Wall St. has put together a preview of some of the world’s largest biotech and pharma companies reporting their earnings on Thursday.
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
